You can spend months building medical imaging software, only to discover a costly surprise. One wrong FDA classification can delay your launch or keep your product off the US market.
That’s the reality for many healthcare software companies. Whether you’re developing a DICOM viewer, PACS platform, or AI-powered imaging solution, understanding the FDA regulations for medical imaging software is essential from the start.
In this guide, you’ll learn:
- What the FDA considers a medical device
- The PACS to MIMPS change and why it matters
- How medical imaging software is classified
- Which FDA pathway, 510(k), De Novo, or PMA, fits your product
- A step-by-step roadmap to FDA clearance
- The latest AI compliance requirements
By the end, you’ll know exactly where your product fits, which regulatory pathway to follow, and how to build compliant medical imaging software with confidence.
What Counts as Medical Imaging Software Under FDA Rules?
Not all medical imaging software is regulated by the FDA. What matters isn’t whether your software works with medical images, but what it’s designed to do.
If your software analyzes, processes, or helps diagnose a medical condition, it’s likely regulated as a medical device. If it simply stores, displays, or transfers images without influencing clinical decisions, it may not fall under FDA regulation.
Understanding this distinction is the first step toward choosing the right regulatory pathway.
1. Software as a Medical Device (SaMD) vs. Embedded Software
Software is considered Software as a Medical Device (SaMD) when it performs a medical function on its own. It does this without being part of a physical medical device. The FDA follows the definition established by the IMDRF.
For example, AI software that detects tumors from CT scans is SaMD because it performs a diagnostic function independently.
In contrast, software built into a CT scanner or MRI machine is embedded software. Since it operates as part of the hardware, it is regulated along with the medical device itself.
2. The Intended Use Test
The FDA regulates software based on its intended use, not just its technical capabilities.
For example, a DICOM viewer marketed to help radiologists detect diseases is making a diagnostic claim and is likely regulated. However, if the same viewer is intended only for education, research, or image reference, it may not require FDA clearance.
This is why your product claims, documentation, and marketing are just as important as the software itself.
3. Which Software Is Not Regulated?
Not every healthcare application is considered a medical device.
General wellness apps, such as fitness trackers, step counters, or sleep monitoring apps, usually fall outside FDA regulation. They do not diagnose or treat medical conditions.
However, once software analyzes medical images or provides information that clinicians use for diagnosis or treatment, it typically becomes subject to FDA regulations. Understanding where your product falls is one of the most important decisions you’ll make before development begins.
The PACS to MIMPS Shift: What Changed and Why
One of the biggest changes in FDA regulations for medical imaging software is the transition from Picture Archiving and Communication Systems (PACS) to Medical Image Management and Processing Systems (MIMPS). Understanding this change is essential because it determines which software functions require FDA regulation.
The change came after the 21st Century Cures Act, which removed certain low-risk software functions from the FDA’s definition of a medical device. To reflect these updates, the FDA replaced the traditional PACS regulation with MIMPS.
Under the current rules, software that only stores, displays, transfers, or converts medical images is generally not regulated as a medical device.
However, software that processes, analyzes, or enhances medical images is still regulated. This includes features such as:
- Image enhancement
- Image segmentation
- Quantitative measurements
- Multi-modality image registration
- 3D visualization
- AI-powered image analysis
In simple terms, moving or viewing medical images is generally exempt, but software that helps clinicians interpret those images remains subject to FDA regulations. This distinction is critical when planning your product’s features and regulatory pathway.
Also Read: What Is The Difference Between DICOM and PACS?
FDA Device Classification for Medical Imaging Software
If your medical imaging software is considered a medical device, the next step is determining its FDA risk class. The FDA divides medical devices into three classes based on the level of risk. Your device class determines the regulatory requirements and approval pathway.
1. Class I: Low Risk
Class I includes low-risk devices. Most are exempt from FDA premarket review, although they must still meet basic requirements such as registration, labeling, and quality controls.
Some basic medical image management tools may fall into this category.
2. Class II: Moderate Risk
Most medical imaging software falls under Class II, including many MIMPS solutions and AI-powered imaging applications.
These devices typically require 510(k) clearance before they can be marketed and must comply with both general and special FDA controls.
3. Class III: High Risk
Class III includes high-risk software that supports critical clinical decisions or could seriously impact patient safety if it fails.
These devices require Premarket Approval (PMA), the FDA’s most rigorous review process, which usually includes clinical evidence.
Note: FDA device classes are different from IMDRF risk categories. The FDA classifies devices based on regulatory risk. The IMDRF instead evaluates software by the severity of the condition and how much it influences clinical decisions.
| Class | Risk level | Controls | Imaging example | Typical pathway |
| Class I | Low | General controls | Basic image management utility | Often exempt |
| Class II | Moderate | General plus special controls | AI triage, MIMPS processing tools | 510(k) |
| Class III | High | General controls plus PMA | Novel life-critical imaging algorithm | PMA |
Not sure which class your product fits? Connect with our experts for a quick, practical read on your options.
FDA Regulatory Pathways for Medical Imaging Software
Once you know your software’s FDA classification, the next step is choosing the right approval pathway. The FDA offers three main pathways, each designed for different types of medical imaging software.
1. 510(k)
The 510(k) pathway is the most common. It’s used when your software is similar to an existing FDA-cleared device (called a predicate device).
To qualify, you must show that your product has the same intended use and performs as safely and effectively as the existing device.
2. De Novo
The De Novo pathway is for new, low-to-moderate risk software that doesn’t have an existing predicate.
Instead of comparing your product to another device, you must demonstrate that it’s safe and effective through a risk-based review.
3. Premarket Approval (PMA)
PMA is the FDA’s most rigorous pathway and is reserved for high-risk medical devices.
It typically requires extensive clinical evidence and is used for software that could significantly impact patient safety if it fails.
Tip: If you’re unsure about your device classification or regulatory pathway, you can request a Pre-Submission (Q-Sub). This allows you to get FDA feedback before submitting your application, helping you avoid costly delays later.
| Pathway | Best for | Evidence | Relative timeline | Relative cost |
| 510(k) | A close, cleared predicate exists | Substantial equivalence plus testing | Shortest | Lowest |
| De Novo | Novel, low-to-moderate risk, no predicate | Risk-based case plus special controls | Medium | Medium |
| PMA | Highest-risk, life-critical software | Clinical evidence | Longest | Highest |
How to Get Your Medical Imaging Software FDA Cleared: Step by Step
Getting FDA clearance may seem complicated, but breaking it into clear steps makes the process much easier. Here’s the roadmap most successful medical imaging software companies follow.
Step 1. Determine Whether Your Software Is a Medical Device
Start by identifying whether your software falls under FDA regulation. If it does, determine its device class (Class I, II, or III), as this decides your regulatory requirements and approval pathway.
Step 2. Choose the Right FDA Pathway
Next, select the appropriate regulatory pathway based on your product.
- 510(k): If your software is similar to an existing FDA-cleared device.
- De Novo: For new low-to-moderate risk software without a predicate.
- PMA: For high-risk software requiring extensive clinical evidence.
Choosing the right pathway early can save months of work.
Step 3. Establish a Quality Management System
Implement a Quality Management System (QMS) before development begins. A strong QMS helps you manage design controls, documentation, testing, and compliance throughout the project.
Step 4. Document Everything
Maintain complete documentation throughout development, including software architecture, design decisions, risk controls, testing results, and AI training data where applicable. Good documentation makes FDA reviews faster and smoother.
Step 5. Perform Risk Management
Identify potential risks, evaluate their impact, and document how your software reduces or eliminates them. Risk management should continue throughout the product lifecycle, not just before submission.
Step 6. Build Security into the Product
Medical imaging software handles sensitive patient data, so cybersecurity must be part of the design from day one. Include threat modeling, vulnerability management, and secure update processes to meet FDA expectations.
Step 7. Validate Performance
Test your software using representative clinical data to prove it performs safely and accurately. For AI-powered imaging software, validate performance across different patient populations and report key metrics such as sensitivity and specificity.
Step 8. Submit and Monitor After Approval
Submit your application through the appropriate FDA pathway and respond promptly to any review questions. After clearance, continue monitoring product performance, manage software updates, and meet post-market surveillance requirements.
Now that you can see the full route to clearance, let us look at the quality and technical requirements that hold it all together.
Quality, Documentation, and Technical Requirements
Meeting FDA requirements isn’t just about submitting an application. You also need to show that your medical imaging software is safe, reliable, and built using proven development practices.
1. Implement a Quality Management System (QMS)
A Quality Management System helps you manage design, development, testing, documentation, and product changes. The FDA’s Quality Management System Regulation (QMSR) now aligns with the globally recognized ISO 13485 standard, making compliance easier across international markets.
2. Follow a Structured Development and Risk Management Process
The FDA expects software to be developed using a structured lifecycle with continuous risk management. Document how you build, test, verify, and reduce risks throughout development, not just before release.
3. Build Cybersecurity into Your Software
Medical imaging software often stores and transfers sensitive patient data. That’s why the FDA expects security to be built into the product from the beginning, including threat modeling, vulnerability management, and secure software updates.
4. Maintain Complete Documentation
Keep detailed records of your software architecture, development process, testing, risk controls, and, for AI solutions, model design and training data. Well-organized documentation can significantly speed up the FDA review process.
5. Validate Software Performance
If your software measures, analyzes, or interprets medical images, you must prove that it produces accurate and reliable results using representative clinical data.
6. Support Industry Standards
Your software should support healthcare interoperability standards such as DICOM, HL7, and FHIR. These standards help your solution exchange medical images and patient data seamlessly with other healthcare systems, improving clinical workflows and compliance.
Also Read: Requirements For HIPAA Compliance for Software Development
AI and Machine Learning in Medical Imaging: Special FDA Requirements
AI is transforming medical imaging, but it also comes with additional FDA requirements. Unlike traditional software, AI models can learn, improve, and change over time, which creates new regulatory challenges.
1. Locked vs. Adaptive AI Models
A locked AI model always produces the same result for the same input and is easier for the FDA to evaluate.
An adaptive AI model can change as it learns from new data. Because its behavior evolves over time, it requires additional oversight and monitoring.
2. Predetermined Change Control Plan (PCCP)
The FDA allows developers to plan certain AI model updates in advance through a Predetermined Change Control Plan (PCCP).
With an approved PCCP, eligible updates can be implemented without submitting a new FDA application each time, provided they follow the approved plan.
3. Use High-Quality Training Data
The FDA expects AI models to be trained and validated using representative, high-quality datasets. You should also document model performance across different patient groups and clearly identify any known limitations or potential bias.
4. Monitor AI After Launch
FDA compliance doesn’t end after clearance. AI models should be continuously monitored to ensure they remain accurate and safe as new data, imaging devices, and clinical environments evolve.
A strong post-market monitoring plan helps maintain compliance while ensuring consistent real-world performance.
Also Read: How AI is Enhancing DICOM Medical Imaging Solutions
Cost and Timeline: What FDA Compliance Really Takes
Budgets and schedules depend on your pathway, your risk class, and how much evidence you need. The ranges below are planning guides, not quotes, and every product differs.
| Pathway | Typical review effort | Evidence weight | Planning note |
| 510(k) | Months, with a predicate in hand | Moderate | Fastest when a clean predicate exists |
| De Novo | Longer than a 510(k) | Higher | Budget for special-controls work |
| PMA | The longest route | Highest | Plan for clinical studies and deep review |
Beyond the review itself, three cost drivers shape most budgets. A quality management system takes real setup effort, and thorough documentation takes engineering time. Validation can be the largest single line for AI tools.
6 Common FDA Compliance Mistakes in Imaging Software
Most delays come from a handful of avoidable errors. Knowing them in advance is the simplest way to protect your timeline and budget.
Mistake 1. Misjudging device status
Many teams assume their tool is a simple utility, only to learn it makes a regulated claim. This misread often surfaces after launch, when a fix is expensive, so an early intended-use check prevents the whole problem.
Mistake 2. Retrofitting the quality system
Building the product first and adding a quality system later is a classic trap. The FDA expects design decisions to be documented as they happen, so a late system usually forces rework and lost time.
Mistake 3. Skipping software lifecycle discipline
Rushing code without following a software lifecycle standard leaves gaps reviewers notice quickly. Missing verification and traceability records slow the whole submission, while disciplined engineering keeps the review clean.
Mistake 4. Under-documenting AI training data
For imaging AI, thin documentation of training data is a frequent stumbling block. Regulators want representative data, subgroup performance, and honest limits, and careful records protect both your clearance and your patients.
Mistake 5. Treating clearance as one and done
A clearance covers a specific version and intended use, not every future update. Significant changes can require a new submission, and a change control plan only covers what you planned in advance.
Mistake 6. Ignoring post-market duties
Some teams pour everything into the submission and neglect what comes after. Post-market monitoring, especially for AI, is now a core expectation, so a simple surveillance plan from day one keeps you compliant.
Why Healthcare Teams Choose DreamSoft4U for Compliant Imaging Software
We engineer compliance-grade medical imaging software, from DICOM and PACS platforms to AI-driven diagnostic tools, with security built in from day one. Our healthcare software development teams pair deep domain knowledge with production-grade engineering for a global client base.
- 22+ years of experience: More than two decades of engineering healthcare and enterprise software.
- 1600+ projects delivered: A track record across EMR, imaging, telehealth, and AI systems.
- 100+ engineers: Domain-deep teams across the US and India serving clients worldwide.
- Compliance-first builds: HIPAA-compliant, secure-by-design, and DICOM, HL7, and FHIR interoperable.
Build Compliant Medical Imaging Software with DreamSoft4U
From FDA classification to AI compliance, our healthcare software experts help you build DICOM, PACS, and AI-powered imaging solutions the right way, the first time.
Conclusion
Medical imaging software rules reward teams that plan early and build with intent. Once you know whether your product is a device, where it sits by risk, and which pathway fits, the rest becomes a clear sequence.
The PACS to MIMPS change, the classification tiers, and the AI expectations all point to one lesson. Compliance works best when it is engineered in from the first sprint.
We hope this guide helped you understand how the FDA regulations for medical imaging software work in practice. Now it is your turn to map your product against these steps and move with confidence.
When you want an experienced partner, connect with our experts to get a clear, practical roadmap for your build.
FAQs
Yes and no, depending on the function. The pure storage, display, and transfer features of a classic PACS are no longer device functions, but advanced processing and analysis still are. The regulation itself was renamed to MIMPS.
In most cases, medical imaging software does need a 510(k). It is usually Class II and reaches the market by matching a cleared predicate. Tools that only store or display images often fall outside device rules.
SaMD performs a medical purpose on its own, independent of hardware, so it is regulated in its own right. Software built into a device, like scanner firmware, is regulated as part of that machine instead.
Usually not, if it only displays and manages images. The moment a viewer adds processing, measurement, or AI detection that informs diagnosis, it crosses into regulated territory and needs the right pathway.
It uses the same core pathways, but with extra expectations. Adaptive models need strong data documentation, monitoring, and often a Predetermined Change Control Plan to handle planned updates without a new submission each time.
